Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
Key claim: Novel flavonoid senotherapeutics identified by phenotypic drug discovery reduce cellular senescence and improve multiple markers of healthspan.
Abstract
Aging Cell, Volume 25, Issue 10, October 2026.
Why this matters
Phenotypic (as opposed to target-based) drug discovery is one of the few routes that has reliably produced senotherapeutics, and flavonoids already dominate the clinical senolytic pipeline through quercetin and fisetin. Adding more flavonoid hits widens the chemical space the field can draw on but does not change the central translation gap: preclinical multi-marker healthspan gains from this chemotype have so far only partially transferred to human endpoints.